Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes
Open Access
- 12 June 2022
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (6) , e882
Abstract
Background: Targeted drugs have greatly improved the therapeutic outcome of non‐small cell lung cancer (NSCLC) patients compared with conventional chemotherapy, whereas about one‐third of patients are so far not suitable for targeted therapy due to lack of known driver oncogenes such as a mutated receptor tyrosine kinase (RTK) genes. In this study, we aimed to identify therapeutic targets for this subgroup of NSCLC patients.Methods: We performed genome‐wide CRISPR/Cas9 screens in two NSCLC cell lines carrying wild‐type TP53 and receptor tyrosine kinase (wtTP53‐RTK) genes using a GeCKO v2.0 lentiviral library (containing 123411 sgRNAs and targeting 19050 genes). MAGeCKFlute was used to analyse and identify candidate genes. Genetic perturbation and pharmacological inhibition were used to validate the result in vitro and in vivo.Results: The Genome‐wide CRISPR/Cas9 screening identified MDM2 as a potential therapeutic target for wtTP53‐RTK NSCLC. Genetic and pharmacological inhibition of MDM2 reduced cell proliferation and impaired tumour growth in the xenograft model, thus confirming the finding of the CRISPR/Cas9 screening. Moreover, treatment by a selective MDM2 inhibitor RG7388 triggered both cell cycle arrest and apoptosis in several NSCLC cell lines. Additionally, RG7388 and pemetrexed synergistically blocked the cell proliferation and growth of wtTP53‐RTK tumours but had limited effects for other genotypes.Conclusions: We identified MDM2 as an essential gene and a potential therapeutic target in wtTP53‐RTK NSCLC via a genome‐wide CRISPR/Cas9 screening. For this subgroup, treatment by RG7388 alone or by its combination with pemetrexed resulted in significant tumour inhibition.Keywords
Funding Information
- National Natural Science Foundation of China (NSFC 81972188, NSFC 81672962, NSFC 3217050420)
This publication has 39 references indexed in Scilit:
- Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft ModelsJournal of Thoracic Oncology, 2015
- High-throughput functional genomics using CRISPR–Cas9Nature Reviews Genetics, 2015
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human CellsScience, 2014
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical DevelopmentJournal of Medicinal Chemistry, 2013
- p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumorsCell Cycle, 2010
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expressionJournal of Cancer Research and Clinical Oncology, 2005
- MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)Lung Cancer, 2004
- MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumorsInternational Journal of Cancer, 1995